Psoriasis is a chronic skin disease, which affects about 2% of the general population. Recently, it is suggetsed that it is a T-cel mediated disease. Clinical features of psoriasis vulgaris are erythematous, hyperkeratotic plaques on the extensor sides of the extremities, scalp and buttocks. About three quarters of the psoriasis patients can be treated effectively with topical therapies such as emolliantia, corticostreoids, vitamine D-derivatives and retinoids. Systemic therapy is reseverde for those with severe psoriasis. Standard, longterm therapies are psoralen+UVA (PUVA, methotrexate, acitretin and cyclosporin.
New pathophysiologic insights in the underlyi,ng mechanisms of psoriasis has resulted in a boom of new biologic therapies. These new therapies are `selective immunemodulators' and aim to inhibit the immunologic component of the disease. However, the first clinic trails demonstrate moderate results. Moreover, the long term safety of these drugs have not been well documented. Biologic therapies ere very costly and cost benefit analyses have not been published yet.
The availability of new psoriasis therapies is a positive development, but should also be an incentive to re-evaluate existing therapies to assess the indicvations of the new therapies. To adress these questions we used two databases (The PUVA Follow up Study and the Psoriasis Foundation surveys). We set out to evalaute the awareness, the use, satisfaction and sideeffects of FDA approved psoriasis treatments.